KIR3DS1 directs NK cell-mediated protection against human adenovirus infections

  • Johannes M Jung
  • Wilhelm Ching
  • Martin E Baumdick
  • Helga Hofmann-Sieber
  • Jens B Bosse
  • Tobias Koyro
  • Kimberly J Möller
  • Lucy Wegner
  • Annika Niehrs
  • Kristina Russu
  • Mareike Ohms
  • Wenli Zhang
  • Anja Ehrhardt
  • Kevin Duisters
  • Eric Spierings
  • Angelique Hölzemer
  • Christian Körner
  • Suze A Jansen
  • Sven Peine
  • Ingo Königs
  • Marc Lütgehetmann
  • Daniel Perez
  • Konrad Reinshagen
  • Caroline A Lindemans
  • Marcus Altfeld (Geteilte/r Letztautor/in)
  • Mirjam Belderbos (Geteilte/r Letztautor/in)
  • Thomas Dobner (Geteilte/r Letztautor/in)
  • Madeleine J Bunders (Geteilte/r Letztautor/in)

Abstract

Human adenoviruses (HAdVs) are a major cause for disease in children, in particular after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, effective therapies for HAdV infections in immunocompromised hosts are lacking. To decipher immune recognition of HAdV infection and determine new targets for immune-mediated control, we used an HAdV infection 3D organoid system, based on primary human intestinal epithelial cells. HLA-F, the functional ligand for the activating NK cell receptor KIR3DS1, was strongly up-regulated and enabled enhanced killing of HAdV5-infected cells in organoids by KIR3DS1+ NK cells. In contrast, HLA-A and HLA-B were significantly down-regulated in HAdV5-infected organoids in response to adenoviral E3/glycoprotein19K, consistent with evasion from CD8+ T cells. Immunogenetic analyses in a pediatric allo-HSCT cohort showed a reduced risk to develop severe HAdV disease and faster clearance of HAdV viremia in children receiving KIR3DS1+/HLA-Bw4+ donor cells compared with children receiving non–KIR3DS1+/HLA-Bw4+ cells. These findings identify the KIR3DS1/HLA-F axis as a new target for immunotherapeutic strategies against severe HAdV disease.

Bibliografische Daten

OriginalspracheEnglisch
Aufsatznummereabe2942
ISSN2470-9468
DOIs
StatusVeröffentlicht - 17.09.2021
PubMed 34533978